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Efficient delivery of tumour-associated antigens to appropriate cellular compartments of antigen-presenting cells is of prime
importance for the induction of potent, cell-mediated antitumour immune responses. We have designed novel multivalent liposomal
constructs that co-deliver the p63–71 cytotoxic T Lymphocyte epitope derived from human ErbB2 (HER2), and HA307–319, a
T-helper (Th) epitope derived from influenza haemagglutinin. Both peptides were conjugated to the surface of liposomes via a
Pam3CSS anchor, a synthetic lipopeptide with potent adjuvant activity. In a murine model system, vaccination with these constructs
completely protected BALB/c mice from subsequent s.c. challenge with ErbB2-expressing, but not ErbB2-negative, murine renal
carcinoma (Renca) cells, indicating the induction of potent, antigen-specific immune responses. I.v. re-challenge of tumour-free
animals 2 months after the first tumour cell inoculation did not result in the formation of lung tumour nodules, suggesting that long-
lasting, systemic immunity had been induced. While still protecting the majority of vaccinated mice, a liposomal construct lacking the
Th epitope was less effective than the diepitope construct, also correlating with a lower number of CD8
þ IFN-g
þ T-cells identified
upon ex vivo peptide restimulation of splenocytes from vaccinated animals. Importantly, in a therapeutic setting treatment with the
liposomal vaccines resulted in cures in the majority of tumour-bearing mice and delayed tumour growth in the remaining ones. Our
results demonstrate that liposomal constructs which combine Tc and Th peptide antigens and lipopeptide adjuvants can induce
efficient, antigen-specific antitumour immunity, and represent promising synthetic delivery systems for the design of specific
antitumour vaccines.
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The identification of tumour-associated antigens (TAA) and TAA
peptide epitopes recognised by cytotoxic T lymphocytes (CTLs) in
the context of major histocompatibility complex (MHC) class I
molecules has provided the basis for the development of specific
cancer immunotherapies aimed at the activation of potent T-cell-
mediated immune responses against cancer cells (Van Der
Bruggen et al, 2002; Finn, 2003). Peptides representing Tc epitopes
of TAAs can be used to prepare structurally defined synthetic
vaccines and their use, which may be particularly advantageous,
has been validated in model systems. However, although injection
of antigenic peptides together with adjuvants like GM-CSF, or
application of peptide-pulsed dendritic cells in some cases,
resulted in antigen-specific T-cell responses in cancer patients,
so far clinical responses have only rarely been observed (Ja ¨ger
et al, 2002; Finn, 2003). Owing to the limited success of such
peptide-based vaccines in the clinic, attempts are being made to
improve vaccine formulations by including, for example, synthetic
vectors and adjuvants to enhance in vivo tumour antigen uptake
and presentation by professional antigen-presenting cells (APCs)
such as dendritic cells (DCs), and optimise the induction of T-cell
responses (Sheikh et al, 2000; Tartour et al, 2000).
The aim of our study was the design of a peptide-based cancer
vaccine construct consisting of well-characterised synthetic
components able to generate a powerful cell-mediated immune
response against tumour cells. We have developed a novel
liposomal formulation for in vivo delivery of a Tc peptide epitope
of the shared TAA ErbB2 (HER2/neu) as a clinically relevant model
antigen (Disis et al, 1994). The ErbB2 molecule is an EGF-receptor-
related receptor tyrosine kinase that belongs to the class of
unmodified self-antigens. Gene amplification and ErbB2 over-
expression have been observed in many human tumours of
epithelial origin and have been linked with cancer development
and progression (Olayioye et al, 2000). Several HLA-A2 restricted
ErbB2 peptide epitopes have been defined, including epitopes
recognised by ex vivo stimulated CTLs on ovarian, breast, renal
cell carcinoma, gastric cancer and melanoma cells (Fisk et al, 1995;
Peoples et al, 1995; Brossart et al, 1998; Kono et al, 1998; Rongcun
et al, 1999). While it could be shown that vaccination of cancer
patients with ErbB2 peptide vaccines can induce or enhance
ErbB2-specific immune responses, this did not result in clinical
responses (Knutson et al, 2001).
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sThe use of liposomes as potential carriers for vaccines has been
extensively explored (Alving et al, 1995). Among their many
advantages, these vesicles are characterised by a marked absence of
toxicity and a low intrinsic immunogenicity. In addition,
liposomes, because of their architecture/size and composition,
offer a wide range of options for the design of effective synthetic
peptide formulations to elicit both humoral and cell-mediated
immune responses (Bergers et al, 1995). Thus, the antigens can be
attached to the outer surface, encapsulated free within the internal
aqueous space or incorporated within the lipid bilayers of the
liposomes. The same liposomes can also play the role of carriers
for various adjuvants such as monophosphoryl lipid A, lipopep-
tides, CpG or cytokines operative in the activation of APCs (Singh
and O’Hagan, 2002). An important advantage of the use of these
vesicles as vaccine vectors resides also in: (i) their ability to be
efficiently endocytosed by APCs such as immature dendritic cells
(Chikh and Schutze-Redelmeier, 2002), the key players in
antitumour host responses (Whiteside and Odoux, 2004), and
(ii) the finding that Tc antigens associated with liposomes can be
efficiently processed by these APCs for MHC class-I-dependent
cross-presentation to CTLs (Alving and Wassef, 1994; Rothwell
et al, 2000; Machy et al, 2002). Multiepitope vesicles can also be
conveniently made (Boeckler et al, 1999), that can carry different
Tc peptide epitopes, or combinations of Tc epitopes with T-helper
(Th) epitopes; this latter strategy is particularly appealing, because
CD4
þ T-cell responses are believed to play a key role in tumour
immunity such as, for example, in vivo CD8
þ T-cell response
priming (Wang and Livingstone, 2003) and/or memory generation
(Bourgeois and Tanchot, 2003). Finally, with respect to the priming
of class I-restricted CTLs, it was shown previously that lipidated Tc
peptide epitopes (e.g. conjugated to palmitoic acid) become highly
efficient activators of CTLs (Schild et al, 1991; Gahery-Segard et al,
2000). Such lipid tails provide the covalently linked peptide moiety
with intrinsic adjuvant activity (Vitiello et al, 1995), and allow
the anchoring of the peptide to liposomes. A similar result can
be achieved by conjugating Tc epitopes to lipopeptides such as S-
[2,3-bis(palmitoyloxy)-(2RS)-propyl]-N-palmitoyl-(R)-cysteinyl-(S)-
seryl-(S)-serine (Pam3CSS) (Deres et al, 1989; Wiesmuller et al,
1992), that is, molecularly defined adjuvants which are also known
to stimulate the maturation of DCs via Toll-like receptor 2 (Hertz
et al, 2001). Altogether, such liposomes are very appealing because
they can combine, within a single construct, all the molecular
elements that are necessary to elicit a highly effective antitumour
immune response by channelling, in vivo, the tumour antigens into
the DC-presentation pathways, and by provoking the differentia-
tion of these cells into potent immunostimulatory APCs.
Here we report on the construction of monoepitope and
diepitope liposomal vaccines designed to induce powerful,
ErbB2-specific immune responses in vivo. As a Tc epitope, these
constructs carry the ErbB2 peptide p63–71, which is efficiently
presented by murine H-2K
d (Nagata et al, 1997). In addition, the
diepitope construct contains a potent Th peptide derived from
influenza virus haemagglutinin. Both peptides were coupled to the
surface of the carrier vesicles via a synthetic Pam3CSS lipopeptide
anchor. The ability of the liposomal vaccines to induce ErbB2-
specific CTL responses and their antitumoral effects were
investigated in immunocompetent BALB/c mice, using ErbB2-
expressing murine renal carcinoma cells as a model.
MATERIALS AND METHODS
Lipids and peptides
Egg yolk L-a-phosphatidylcholine (PC), L-a-phosphatidyl-DL-gly-
cerol (PG) transesterified from egg yolk PC and cholesterol (Chol)
were purchased from Sigma-Aldrich (Saint Quentin Fallavier,
France), and their purities (over 99%) were assessed by thin-layer
chromatography. The lipopeptide Pam3CSS, prepared as pre-
viously described (Fernandes et al, 1997), was converted into the
maleimide derivative Pam3CSS-maleimide (Pam3CSS-Mal) by
reaction with 1-(2-aminoethyl)-pyrrole-2,5-dione according to
Boeckler et al (1998). The two peptides ErbB2 p63–71 (CG-
TYLPTNASL) and influenza virus haemagglutinin-derived HA307
–319 (PKYVKQNTLKLAT-C) were obtained from Neosystem
(Strasbourg, France). The cysteine or cysteinyl-glycine residues
added to the C- or N-terminus of the peptides allow their facile
coupling on the lipopeptide maleimide function. The purity of the
peptides, as assessed by HPLC, was at least 80%.
Preparation of liposomes
Liposomes were prepared by mixing phospholipids (PC, PG) and
cholesterol, in a 75/20/50 molar ratio, in chloroform with the thiol-
reactive functionalised lipopeptide Pam3CSS-Mal at 5mol%, in a
round-bottom flask (Boeckler et al, 1999). After solvent evapora-
tion under high vacuum, the dried lipid film was hydrated in 1ml
10mM Hepes buffer (pH 6.5) containing 5% (wv
 1) sorbitol by
vortex mixing (1ml for 10mmol lipids). The suspension was
sonicated at 251C (i.e. above the phase transition temperature of
the lipids) for 1h (5s cycles interrupted for 1.25s) under a
continuous flow of nitrogen, using a 3mm diameter probe
sonicator (Vibra Cell, Sonics and Material Inc., Danbury, CT,
USA) at 300W. The small unilamellar vesicles preparation was
finally centrifuged for 10min at 10000g to remove the titanium
dust originating from the probe.
Peptide conjugation
ErbB2 and HA peptides were coupled by reacting freshly prepared
liposomes containing Pam3CSS-Mal with the ErbB2 peptide alone
(0.5molar eq. of peptide vs surface accessible thiol-reactive
maleimide function), or with the two peptides (ErbB2 and HA)
in equimolar quantities (0.5 molar eq. of each peptide vs surface
accessible thiol-reactive maleimide function). Coupling was
performed, under argon, in 10mM Hepes buffer (pH 6.5) contain-
ing 5% (wv
 1) sorbitol, after reduction of the disulphide bonds of
oxidised peptides with tris(2-carboxyethyl)phosphine (Sigma-
Aldrich, Saint Quentin Fallavier, France) (0.7 eq. vs peptide). After
2h at 251C, a 10-fold excess of 2-mercaptoethanol was added to the
preparation to derivatise all unreacted maleimide groups. This step
was performed for 1h under argon. Then, the liposomal
preparation was dialysed extensively against 10mM Hepes buffer
(pH 7.4) containing 5% (wv
 1) sorbitol, to eliminate unconjugated
peptides and excess reagents. The phosphorous content of
liposomes was analysed by a previously described method (Rouser
et al, 1970).
Quantification of the peptides associated to vesicles was
achieved by acid hydrolysis of the liposomal formulations
(Boeckler et al, 1999). The amino acids that were generated were
measured using a fluorimetric assay with fluorescamine (Bo ¨hlen
et al, 1973) as follows: 50ml of the hydrolysis solution (containing
10–50nmol of amines) was added to 1.5ml of 50mM sodium
borate buffer (pH 9.0), followed by the addition of 500mlo fa
fluorescamine solution in dioxane (300mgml
 1). After mixing, the
fluorescence was read immediately at lem¼475nm
(lexc¼390nm). The contribution of the liposomes alone was
evaluated using the same hydrolysis conditions, and subtracted
from the total fluorescence. Hydrolysis of known quantities of free
peptides was used as standard. The coupling yields were calculated
vs the quantity of surface-exposed maleimide functions. The
liposomal preparations were then concentrated using a Centricon
type YM-100 (Millipore Corporation, Bedford, MA, USA) until a
concentration of about 15mg ErbB2 peptide per 100ml was reached
for injections into mice. The vesicle size was measured as
described below, prior and after the conjugation of the peptide.
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cryoprotectant (5% glucose) and stored at  201C until use.
Light-scattering measurements
Liposome size was determined by dynamic light scattering using a
Zeta-master 3000 (Malvern instruments, Paris, France) with the
following specifications: sampling time, 30s; medium viscosity,
1.014cP; refractive index, 1.34; scattering angle, 901; temperature,
251C. Data were analysed using the multimodal number distribu-
tion software included with the instrument. All the formed vesicles
were uniformly distributed in size and exhibited average diameters
of 65715nm, which, under our experimental conditions,
remained unaffected by the freezing process.
Cell lines and cell culture conditions
Murine renal carcinoma (Renca) cells stably expressing Escherichia
coli b-galactosidase (Renca-lacZ) were maintained in RPMI 1640
(BioWhittaker, Verviers, Belgium) supplemented with 10% FBS
(PAA Laboratories, Co ¨lbe, Germany), 2mM glutamine, 100Uml
 1
penicillin, 100mgml
 1 streptomycin and 0.25mgml
 1 Zeocin.
Renca-lacZ/ErbB2 cells expressing human ErbB2 (Maurer-Gebhard
et al, 1998) were cultured in the same medium in addition
containing 0.5mgml
 1 G418.
Antibodies
Anti-CD16/CD32mAb 2.4G2 was purchased from BD PharMingen
(Heidelberg, Germany), horseradish peroxidase (HRP)-coupled
anti-mouse IgG antibody from Sigma-Aldrich (Deisenhofen,
Germany). Cy5-conjugated anti-CD8a mAb YTS169 and FITC-
conjugated anti-IFN-g mAb XMG1.2 were kindly provided by HW
Mittru ¨cker, Max-Planck-Institut fu ¨r Infektionsbiologie, Berlin,
Germany.
Restimulation of splenocytes and evaluation of T-cell
responses
Female BALB/c mice of 15–17g body weight (Charles River,
Sulzfeld, Germany) were vaccinated by subcutaneous (s.c.)
injection of Tc-ErbB2 liposomes, Tc-ErbB2/Th-HA liposomes or
peptide-free liposome carrier on days 0 and 14. Amounts of
liposomal formulations injected were adjusted for each mouse to
receive 15mg of coupled Tc-ErbB2 peptide per injection. Im-
portantly, the doses of (phospho)lipids injected were equivalent
for all groups. At 5 days after the last vaccination, mice were killed,
spleens were removed and single-cell suspensions were obtained
by scraping organ tissues through a stainless steel mesh, followed
by erythrocyte lysis. For detection of IFN-g-expressing cells by flow
cytometry, 1 10
6 resuspended splenocytesml
 1 were stimulated
for 5h at 371C with 10mgml
 1 of H-2K
d restricted ErbB2 p63-71
peptide TYLPTNASL (Thermo Hybaid, Ulm, Germany). During
the final 4h of incubation, 10mgml
 1 Brefeldin A (Sigma-Aldrich)
was added. Cells were washed and incubated for 10min with
2mgml
 1 anti-CD16/CD32 (Fc-blockt) and 10mgml
 1 rat serum
(Sigma-Aldrich) to block unspecific binding. Then cells were
stained with Cy5-conjugated anti-CD8a mAb for 30min at 41C.
Subsequently, cells were washed with PBS, fixed with 4%
paraformaldehyde in PBS for 20min at RT, and permeabilised
with PBS, 0.1% BSA, 0.5% Saponin (Sigma-Aldrich) in the
presence of 2mgml
 1 anti-CD16/CD32 and 10mgml
 1 rat serum.
Then FITC-conjugated anti-IFN-g mAb was added for 30min at
RT, cells were washed with PBS, transferred to PBS containing 1%
paraformaldehyde, and analysed using a FACSCalibur flow
cytometer.
Detection of peptide-specific serum antibodies
For detection of peptide-specific antibodies in murine sera by
enzyme-linked immunosorbent assay (ELISA), approximately 50ml
of peripheral blood was collected from the tail vein of vaccinated
mice at day 21 after the first immunization. Coagulated blood was
separated from the serum by centrifugation at 4000r.p.m. in a
tabletop centrifuge (Hettich, Tuttlingen, Germany). Ninety-six-well
ELISA plates (Nunc, Wiesbaden, Germany) were coated overnight
at 41C with 5mgml
 1 of ErbB2 peptide dissolved in bicarbonate
buffer (pH 9.6), washed with PBS, 0.05% Tween 20, and blocked
with 2% BSA in PBS for 2h at 371C, before 1:100 dilutions of
serum samples were added. After 2h of incubation at 371C, plates
were washed and HRP-conjugated secondary anti-mouse IgG
antibody (Sigma-Aldrich) was added for 1h at 371C. After a final
washing step, bound antibody complexes were detected by
incubation with HRP-substrate ABTS (Roche, Mannheim, Germany)
for 20min at RT in the dark, followed by analysis of the absorption
at 405/650nm in an ELISA reader.
Protective and therapeutic vaccination
BALB/c mice were vaccinated by s.c. injection of Tc-ErbB2 or
Tc-ErbB2/Th-HA liposomes in an amount corresponding to 15mg
of coupled Tc-ErbB2 peptide on days 0 and 14. On day 20, mice
were inoculated with Renca-lacZ/ErbB2 or Renca-lacZ tumour cells
by s.c. injection of 5 x 10
6 cells into each flank. At regular intervals,
two perpendicular tumour diameters were measured with a caliper,
and tumour volumes were calculated according to the formula:
length (width)
2 0.4. For therapeutic vaccination, naı ¨ve BALB/c
mice were first inoculated with Renca-lacZ/ErbB2 cells as
described above. At day 2 after tumour cell injection, when
tumours were palpable, animals were treated by s.c. injection of
Tc-ErbB2 or Tc-ErbB2/Th-HA liposomes in an amount corre-
sponding to 7.5mg of coupled Tc-ErbB2 peptide, or peptide-free
liposome carrier into the vicinity of each tumour. Treatment was
repeated on day 6 and tumour growth was followed as described
above. To avoid suffering of the animals, in all cases mice were
killed latest when tumour size reached 0.8cm
3.
Long-term protection was investigated by intravenous re-
challenge of surviving animals with 5 10
5 Renca-lacZ/ErbB2
tumour cells 70 days after initial tumour cell inoculation. Cells
were suspended in 100ml PBS and injected into the lateral tail vein.
After 28 days, before mice developed any apparent disease
symptoms, they were killed, lungs were excised, and pulmonary
tumour nodules were visualised by X-gal staining and counted as
described previously (Maurer-Gebhard et al, 1998). All animal
experiments had been approved by the Regierungspra ¨sidium
Darmstadt, Germany, as the responsible government committee,
and were conducted in a manner consistent with the guidelines of
the UKCCCR.
RESULTS
Preparation of liposomal vaccine constructs
Liposomal constructs were prepared by conjugation of the
peptides TYLPTNASL (p63–71), derived from human ErbB2
(Nagata et al, 1997), and PKYVKQNTLKLAT (HA307–319), a
promiscuous Th epitope derived from influenza virus haemagglu-
tinin (HA) (O’Sullivan et al, 1991), to the surface of preformed
small unilamellar vesicles under well-defined conditions that allow
a chemoselective ligation of purified molecular species (Boeckler
et al, 1999; Schelte ´ et al, 2000) (Figure 1). The vesicles were
obtained from egg phosphatidylcholine, phosphatidylglycerol and
cholesterol in a 75/20/50molar ratio, and the thiol-reactive
maleimide-functionalised lipopeptide Pam3CSS-Mal (Boeckler
et al, 1998) was added at a 5mol% ratio. This amphiphatic
Liposomal ErbB2/HER2 cancer vaccines
A Roth et al
1423
British Journal of Cancer (2005) 92(8), 1421–1429 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
slipopeptide, which serves as anchor for both Tc and Th epitopes,
was selected because it is known to efficiently target exogenous
antigens to the MHC class I/II-restricted presentation pathways in
APCs (Deres et al, 1989; Bessler and Jung, 1992). Owing to the
coupling strategy, the two peptides were functionalised with a thiol
group via the introduction at their N- or C-terminus of a cysteinyl-
glycine or a cysteine linker (see Materials and methods). The
determination of peptides coupled to the surface of the liposomes
showed a global yield of 90% for the diepitope construct (Tc-
ErbB2/Th-HA liposomes) and 100% for the mono-epitope
construct (Tc-ErbB2 liposomes). A uniform size distribution of
vesicles was obtained with a mean diameter of 65715nm, which
was unaffected by the coupling step.
Protection of mice from challenge with ErbB2-expressing
tumour cells
To investigate whether immunisation with liposomal vaccine
constructs can induce antitumour immunity and protect animals
from subsequent tumour challenge, we used a model that allows
evaluation of ErbB2-specific reagents in immunocompetent mice.
This model is based on BALB/c-derived renal carcinoma (Renca)
cells, which form solid tumours or lung tumour nodules in BALB/c
mice upon s.c. and i.v. injection, respectively (Murphy and
Hrushesky, 1973). Importantly, it was shown previously that
Renca cell variants which express E. coli b-galactosidase
(Renca-lacZ), or coexpress b-galactosidase and human ErbB2
(Renca-lacZ/ErbB2), are not rejected by naı ¨ve immunocompetent
animals (Maurer-Gebhard et al, 1998). Moreover, the H-2K
d-
restricted ErbB2 peptide TYLPTNASL (p63-71) serving as a Tc
epitope in the liposomal vaccine formulations can be efficiently
presented in BALB/c mice (Nagata et al, 1997).
Mice were vaccinated twice on days 0 and 14 by s.c. injection of
Tc-ErbB2 or Tc-ErbB2/Th-HA liposomes, corresponding to 15mg
of coupled Tc-ErbB2 peptide per injection. Control animals
received PBS. This route of administration was chosen because
the skin contains DCs previously demonstrated to actively
promote CTL activity (Campton et al, 2000), and because after
application liposomes distribute preferentially via the lymph
reaching local organised lymphoid tissues (Oussoren and Storm,
2001). At 6 days after the last vaccination, mice were challenged by
s.c. injection of Renca-lacZ/ErbB2 cells into each flank, and
tumour growth was followed. Tumour-free survival of the animals
is shown in Figure 2A, tumour growth kinetics are shown in
Figure 2B. Whereas early onset of tumour growth was observed in
the majority of the PBS-treated control animals, three out of five
mice vaccinated with the Tc-ErbB2 construct rejected Renca-lacZ/
ErbB2 tumour challenge and remained tumour free for the
complete duration of the experiment until day 96. Vaccination
with Tc-ErbB2/Th-HA liposomes was even more effective, result-
ing in complete protection of all five mice in this group from
outgrowth of Renca-lacZ/ErbB2 tumours.
Protection of vaccinated mice against repeated tumour
challenge
To analyse whether mice vaccinated with liposomal vaccine
preparations were protected against repeated tumour challenge,
mice from the experiment described above that had rejected initial
tumour challenge were re-challenged after day 96 by i.v. injection
of Renca-lacZ/ErbB2 cells. In naı ¨ve animals, i.v. injection of Renca-
lacZ cells results in the formation of pulmonary tumour nodules
which can be detected upon X-gal staining of the organs (Maurer-
Gebhard et al, 1998). As summarised in Table 1, in the control
mice which had not been previously vaccinated and challenged, 4
weeks after i.v. injection of tumour cells more than 250 tumour
nodules had developed on each lung surface. In contrast, all
animals that had received Tc-ErbB2 or Tc-ErbB2/Th-HA liposomes
as vaccines and had rejected initial s.c. Renca-lacZ/ErbB2 tumour
challenge also remained completely free of pulmonary tumour
nodules (Table 1). These results demonstrate that vaccination with
Tc-ErbB2 or Tc-ErbB2/Th-HA liposomes is highly effective and
can protect against repeated challenge with ErbB2-expressing
tumour cells.
Specificity of tumour cell rejection
To test whether antitumoural responses resulting from vaccination
with liposomal constructs were dependent on the expression of
ErbB2 by the tumour cells, two groups of mice were vaccinated
twice on days 0 and 14 by s.c. injection of Tc-ErbB2/Th-HA
liposomes, corresponding to 15mg of coupled Tc-ErbB2 peptide
per injection. At 6 days after the last vaccination, animals from one
group were challenged by s.c. injection of Renca-lacZ/ErbB2 cells
into each flank as described above, the other group was injected
with parental ErbB2-negative Renca-lacZ cells. Tumour growth
kinetics are shown in Figure 3. Whereas all mice vaccinated with
Tc-ErbB2/Th-HA liposomes and challenged with ErbB2-expressing
cells remained tumour free, none of the Tc-ErbB2/Th-HA
vaccinated animals were able to reject challenge with ErbB2
negative but otherwise isogenic tumour cells. These results confirm
that liposomal ErbB2 peptide vaccines induce immune responses
specifically directed against ErbB2-expressing tumours.
Induction of ErbB2-specific T-lymphocytes by liposomal
vaccine constructs
To analyse the nature of the immune responses induced by the
liposomal vaccines, BALB/c mice were immunised twice by s.c.
injection of Tc-ErbB2 liposomes, Tc-ErbB2/Th-HA liposomes, or
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Figure 1 Design of the diepitope liposomal construct. Preformed negatively charged liposomes (PC/PG/Chol, 75/20/50 molar ratio; mean diameter:
65nm) containing 5mol% of the thiol-reactive lipopeptide anchor Pam3CSS-Mal were reacted, at 251C and pH 6.5, with equimolar quantities of the
peptides ErbB2 (p63–71), derivatised with a CG linker at its N-terminus, and HA307-319, derivatised with a C linker at its C-terminus.
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Amounts of liposomal formulations injected were adjusted for
each mouse to receive 15mg of coupled Tc-ErbB2 peptide per
injection. At 5 days after the last vaccination, mice were killed,
splenocytes were isolated, and restimulated ex vivo with ErbB2-
derived synthetic peptide TYLPTNASL for 5h. Activated CD8
þ T
cells were identified by flow cytometry after double-staining of
splenocytes with antibodies detecting CD8 and intracellular IFN-g.
The results shown in Figure 4A demonstrate that immunisation of
mice with both Tc-ErbB2 and Tc-ErbB2/Th-HA liposomes induced
activation of CD8
þ T cells specific for the Tc-ErbB2 epitope.
Importantly, the diepitope construct Tc-ErbB2/Th-HA was more
potent, resulting in a doubling of the absolute numbers of ErbB2-
specific CD8
þ IFN-g
þ T cells when compared to mono-epitope
Tc-ErbB2 liposomes. In contrast, peptide-free liposomal carrier
did not lead to an increase of ErbB2-specific effector cells, with
numbers of CD8
þ IFN-g
þ T cells in this group comparable to
those of untreated animals (data not shown).
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Figure 2 Protective vaccination of BALB/c mice. Five animals per group
were immunised on days 0 and 14 by s.c. injection of Tc-ErbB2/Th-HA
liposomes (J) or Tc-ErbB2 liposomes (K) corresponding to 15mgo f
coupled Tc-ErbB2 peptide per injection. Control animals received PBS
(open diamonds). On day 20, mice were inoculated with Renca-lacZ/ErbB2
tumour cells by s.c. injection into each flank. Tumour growth was followed
by caliper measurements and mean tumour volumes were calculated. (A)
Tumour-free survival. Tumour growth was registered when palpable
tumours had formed at one or both of the injected flanks. (B) Kinetics of
tumour growth of the experiment shown in (A). As indicated by asterisks,
two of the Tc-ErbB2 vaccinated animals had to be killed on day 57 due to
tumour growth. From day 64 onwards, mean tumour volume in this group
was calculated from the remaining three animals. Tumour-bearing mice
were killed latest when tumour size reached 0.8cm
3, to avoid suffering of
the animals.
Table 1 Long-term protection of vaccinated animals
Vaccination Mean number of pulmonary tumour nodules
Tc-ErbB2/Th-HA 0 (n¼5)
Tc-ErbB2 0 (n¼2)
None 4250 (n¼5)
After rejection of initial tumour challenge, tumour-free mice from the experiment
shown in Figure 2 were re-challenged by i.v. injection of Renca-lacZ/ErbB2 cells after
day 96. After 28 days, before mice developed any apparent disease symptoms, they
were killed, lungs were excised, and pulmonary tumour nodules were visualised by X-
gal staining of excised organs and counted. Naı ¨ve animals injected with Renca-lacZ/
ErbB2 cells served as a control. One of the three mice in the Tc-ErbB2 vaccinated
group that had rejected the initial tumour challenge died for unknown reasons before
i.v. re-challenge could be performed.
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Figure 3 Specificity of tumour rejection. Two groups of BALB/c mice
were immunised on days 0 and 14 by s.c. injection of Tc-ErbB2/Th-HA
liposomes corresponding to 15mg of coupled Tc-ErbB2 peptide per
injection. On day 20, one group of animals was inoculated with Renca-lacZ/
ErbB2 tumour cells (open circles) by s.c. injection into each flank. The other
group was injected with ErbB2-negative parental Renca-lacZ cells (filled
diamonds). Tumour growth was followed by caliper measurements and
mean tumour volumes were calculated. Tumour-bearing mice were killed
latest when tumour size reached 0.8cm
3, to avoid suffering of the animals.
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vaccination with peptide-carrying liposomes were also investi-
gated. At day 21 after the first immunisation, sera were collected
from BALB/c mice injected twice with Tc-ErbB2 liposomes or Tc-
ErbB2/Th-HA liposomes as described above, and were tested for
the presence of peptide-specific antibodies by ELISA. Sera from
PBS-treated animals served as a control. As shown in Figure 4B,
none of the mice immunised with Tc-ErbB2 or Tc-ErbB2/Th-HA
liposomes developed antibodies reacting with the Tc-ErbB2
peptide. Taken together, these results indicate that the antitu-
moural activity of the Tc-ErbB2 peptide carrying liposomal
constructs is mediated by a strong, ErbB2-specific T-cell response
induced by the vaccines. Humoral responses did not play a role in
the observed tumour rejection.
Therapeutic vaccination of tumour-bearing animals
The influence of liposomal vaccine constructs on the growth of
established tumours was investigated in animals carrying Renca-
lacZ/ErbB2 tumours. BALB/c mice were inoculated with tumour
cells by s.c. injection into each flank. Upon formation of palpable
tumours (day 2 post tumour cell injection), animals were treated
by s.c. injection of Tc-ErbB2 or Tc-ErbB2/Th-HA liposomes
corresponding to 7.5mg of coupled ErbB2 Tc peptide into the
vicinity of each tumour. Control animals received peptide-free
liposomal carrier. Treatment was repeated 4 days later, and
tumour growth was followed. The results are shown in Figure 5. In
most vaccinated mice, tumour growth continued for a few days
after onset of therapy, before therapeutic effects became apparent
(Figure 5A).
Whereas injection of liposomal carrier had no effect on tumour
growth, and all animals in this group had to be killed due to the
size of their tumours latest until day 43 of the experiment
(Figure 5B), two out of five mice treated by therapeutic vaccination
with mono-epitope Tc-ErbB2 liposomes and three out of five mice
treated with diepitope Tc-ErbB2/Th-HA liposomes had completely
rejected the established tumours by day 20 and remained tumour
free until day 86 when the experiment was terminated. In the
remaining mice of these groups, vaccination resulted in delayed
tumour growth in comparison to the control animals. In addition
to the tumour-free mice, one animal in each group that had
received ErbB2 vaccines developed only small tumours and
therefore did not have to be killed before the end of the
experiment (Figure 5B).
DISCUSSION
The aim of the present study was the design of cancer vaccines
composed of well-characterised synthetic molecules that cooperate
in the activation of a powerful cell-mediated antitumour immune
response. We have used liposomal carriers as multivalent vectors
for Tc and Th peptide epitopes which are covalently linked to the
surface of the vesicles via Pam3CSS, a specific lipopeptide anchor
previously shown to have powerful immunostimulatory activity
(Bessler and Jung, 1992). For the coupling step we made use of a
strategy we have developed previously (Boeckler et al, 1999).
Accordingly, a synthetic lipopeptide derivative such as Pam3CSS-
Mal, which contains a thiol-reactive maleimide function (Boeckler
et al, 1998), was first incorporated into the bilayers of small
unilamellar vesicles (mean dia. 65nm) masking the hydrophobic
nature of the anchor/adjuvant. In the subsequent steps, the peptide
epitopes that carry a free thiol function either at their N- or
C-terminus are conjugated to the surface of these preformed
and functionalised vesicles. This a posteriori coupling of
peptides to lipopeptides is thus achieved under very mild
conditions in aqueous media via a high-yield chemoselective
ligation. For the Tc-ErbB2 liposomal construct, the ErbB2 epitope
p63–71 was used. This peptide can be presented by human HLA-
A2402 (Okugawa et al, 2000), but it has also been shown to be
efficiently presented as an immunodominant CTL epitope by
murine H-2K
d in BALB/c mice (Nagata et al, 1997). Previously,
co-delivery of this peptide with immunostimulatory CpG ODN
encapsulated within liposomes has been demonstrated to induce
ErbB2-specific CTL responses in BALB/c mice (Li et al, 2003).
However, potential antitumoral activity of such vaccines in vivo
was not investigated.
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Figure 4 Evaluation of vaccine-induced immune responses. BALB/c mice
were immunised in separate experiments by s.c. injection of Tc-ErbB2/Th-
HA liposomes (white bars), Tc-ErbB2 liposomes (black bars), or peptide-
free liposome carrier (A) or PBS (B) (hatched bars) on days 0 and 14. (A)
To investigate induction of ErbB2-specific CTLs, 5 days after vaccination
splenocytes were isolated and stimulated with synthetic ErbB2 peptide
before flow cytometric analysis with anti-CD8a and anti-IFN-g antibodies.
Absolute numbers of CD8
þ IFN-g
þ splenocytes are indicated (mean
values from five animals per group). (B) Sera taken at day 21 after the first
vaccination were tested for the presence of peptide epitope-specific
antibodies by ELISA. ErbB2-derived Tc peptide was coated on ELISA plates,
before sera were added. Peptide-specific antibodies were detected by
HRP-conjugated secondary anti-mouse IgG, followed by addition of HRP-
substrate (ABTS) and measuring of the absorbance at 405nm in an ELISA
reader.
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system, we could show in the present study that the mono-epitope
liposomes carrying the Tc-ErbB2 peptide induced protective
cellular immunity against tumour cells expressing human ErbB2,
resulting in the rejection of s.c. implanted Renca-lacZ/ErbB2 cells
in the majority of the vaccinated animals. Thereby immunological
memory was induced, leading to long-term systemic immunity in
the tumour-free animals and complete protection, several months
later, against subsequent re-challenge with intravenously injected
Renca-lacZ/ErbB2 cells. In the second vaccine formulation (Tc-
ErbB2/Th-HA liposomes), in addition to the ErbB2 Tc epitope, a
Th epitope derived from influenza haemagglutinin (HA307-319)
was also coupled to the liposomal carriers. This Th epitope was
chosen because of its promiscuous binding to MHC class II
molecules and recognition by T cells (O’Sullivan et al, 1991). The
diepitope liposomal construct proved to be even more potent as a
cancer vaccine. It protected all vaccinated mice from subsequent
s.c. challenge and i.v. re-challenge with ErbB2-expressing Renca-
lacZ/ErbB2 cells. Importantly, the immune responses initiated
were specifically directed to the ErbB2 antigen. Thus, vaccinated
mice were protected against challenge with Renca-lacZ/ErbB2, but
not against ErbB2-negative Renca-lacZ cells still expressing
bacterial b-galactosidase, which in naı ¨ve animals in our Balb/c-
based model fails to serve as a tumour rejection antigen (Maurer-
Gebhard et al, 1998). This demonstrates that the potent
antitumoral responses observed were not caused solely by broad,
unspecific immunostimulatory activity of the vaccines.
The combination of Tc and Th epitopes in the Tc-ErbB2/Th-HA
liposomes was primarily intended to enhance the function of DCs
and improve activation of CD8
þ T-cells through the recruitment
of CD4
þ T-lymphocytes. Although proper activation of DCs for
induction of CTL responses can be achieved by both CD4
þ-
dependent and independent pathways (Schuurhuis et al, 2000), the
help of Th epitopes and CD4
þ T-lymphocytes has been shown to
be crucial in optimising CTL responses and for efficient and long-
lasting immunity against tumours (Toes et al, 1999). Activation
and maturation of APCs are dependent on licensing signals, one of
which can be provided by activated helper T cells via ligation of
CD40. Then upon CD40 ligation, APCs become ‘licensed’ to prime
CTLs, due to the interaction between CD40 receptor expressed on
the DC and CD40 ligand present on the Th cells, triggering the
production of IL-12 and initiating the CTL response (Koch et al,
1996; Schoenberger et al, 1998). Indeed, in our study addition of
the highly immunogenic Th epitope clearly increased the efficiency
of Tc-ErbB2 liposomes to stimulate T cells specific for the ErbB2-
derived Tc epitope. This is most likely due to helper T cells
activated by DCs presenting the Th epitope. In turn, such helper T
cells could then provide licensing signals towards DCs, thereby
increasing presentation of the Tc epitope and activation of ErbB2-
specific CTLs. Of note, the critical role of helper T cells for the
activation of tumour-specific CTLs has also become apparent in
recent studies with regular ErbB2 peptide vaccines. Vaccination of
cancer patients with a single ErbB2-derived CTL epitope together
with GM-CSF as an adjuvant was not very effective, leading only to
short-lived CTL responses (Knutson et al, 2002). In contrast,
vaccines consisting of different potential ErbB2 Th epitopes also
encompassing a number of HLA-A2 motifs induced long-lived
CD4
þ and CD8
þ T-cell responses (Knutson et al, 2001). However,
so far this has not resulted in clinical responses.
The Th/Tc collaboration in the induction of a CTL response
could be corroborated by the observation that for each liposomal
construct, results from ex vivo restimulation assays and protective
vaccination experiments corresponded well. Indeed, vaccination of
BALB/c mice with either Tc-ErbB2-liposomes or Tc-ErbB2/Th-HA
liposomes induced activation of CD8
þ T cells specific for the
ErbB2-derived Tc epitope TYLPTNASL, as demonstrated by
intracellular IFN-g staining. However, in mice vaccinated with
the diepitope Tc-ErbB2/Th-HA liposomes, a two times higher
number of CD8
þ T cells, most likely CTL, was activated in
comparison to animals that had received mono-epitope Tc-ErbB2
liposomes. A marked enhancement of antitumoral activity of
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Figure 5 Therapeutic vaccination of tumour-bearing animals. BALB/c
mice were inoculated with Renca-lacZ/ErbB2 tumour cells by s.c. injection
into each flank. When tumours were palpable, animals were treated twice
by s.c. injection of Tc-ErbB2/Th-HA liposomes (J), Tc-ErbB2 liposomes
(K), or liposomal carrier as a control (E) into the vicinity of each tumour.
(A) Tumour growth was followed by caliper measurements and mean
tumour volumes were calculated. As indicated by the asterisk, due to
tumour growth one of the Tc-ErbB2/Th-HA- and two of the Tc-ErbB2-
treated animals had to be killed on days 43 and 51, respectively.
Subsequently, mean tumour volumes in these groups were calculated from
the remaining animals. In the control group, all mice were killed due to
tumour growth latest until day 43. (B) Course of the disease in mice from
the experiment shown in (A). In addition to the animals that had
completely rejected their tumours and were tumour free, in each group
treated with Tc-ErbB2/Th-HA or Tc-ErbB2 liposomes one animal
developed only small tumours until day 86 when the experiment was
terminated. All other tumour-bearing mice were killed latest when tumour
size reached 0.8cm
3 to avoid suffering of the animals.
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therapeutic application of the liposomal formulations in tumour-
bearing animals. The induction of ErbB2-specific CD8
þ T cells
clearly indicates that the tested liposomal vaccines activate T-cell-
mediated, antigen-specific antitumour immunity. ErbB2-specific
humoral responses were not induced. Consequently, anti-ErbB2
antibodies were not involved in tumour rejection.
As a tumour antigen, here we have used human ErbB2, which is
a foreign antigen in this system despite a high degree of sequence
identity with its murine counterpart and the fact that Renca-lacZ/
ErbB2 cells are not rejected in naı ¨ve immunocompetent animals.
However, CTLs from Balb/c mice that similar to the CD8
þ T cells
identified in our study, recognise the human ErbB2 epitope
TYLPTNASL have previously been shown to also lyse cells
presenting the corresponding murine ErbB2 peptide TYLPANASL
(Nagata et al, 1997). This indicates that cross-reactive immune
responses are possible, and suggests that at least for this particular
epitope tolerance to endogenous murine ErbB2 might have to be
overcome to mount an effective response against the human
peptide. Subsequent studies in animals such as the recently
described ErbB2/HER2 transgenic mice (Piechocki et al, 2003) will
help to further investigate the potential of liposomal ErbB2
vaccines to break endogenous tolerance against this antigen.
As mentioned above, in the liposomal vaccine constructs
investigated in our study, both Tc and Th peptide epitopes were
conjugated to Pam3CSS, a synthetic analogue of the N-terminus of
E. coli lipoprotein. The choice of this lipopeptide anchor is highly
important for the immune response, since it allows the targeting,
via poorly understood mechanisms (Uhl et al, 1991; Andrieu et al,
2003), of exogenous antigens into MHC class I and class II
restricted pathways. Lipopeptides, such as Pam3CSS, constitute
potent and nontoxic immunoadjuvants which, for example,
activate B lymphocytes (Bessler et al, 1985) and APCs such as
macrophages and DCs (Hertz et al, 2001). Moreover, in vivo, they
are able to induce cell-mediated as well as humoral immune
responses, depending on the nature of the epitope, against low
molecular weight peptides that are covalently coupled to them
(Deres et al, 1989; Wiesmuller et al, 1992). This might explain why
liposomes only containing the lipopeptide-coupled Tc epitope
were also able to induce significant ErbB2-specific immunity and
also why, in the case of Tc-ErbB2/Th-HA liposomes, an additional
help from CD4
þ T cells could be observed. Importantly, in
contrast to lipidated (e.g. palmitoylated) peptides, inclusion of the
Pam3CSS lipopeptide anchor in the liposomal formulations might
also induce Toll-like receptor 2-mediated internalisation by DCs
(Hertz et al, 2001). Immature DCs could thereby become activated
and upregulate costimulatory molecules and MHC class II
expression.
In conclusion, our data demonstrate that effective priming of
ErbB2-specific CD8
þ T cells occurred upon in vivo application of
cancer vaccines consisting of an ErbB2-derived Tc-epitope
attached to a liposomal carrier via an adjuvant Pam3CSS
lipopeptide anchor. The importance of CD4
þ T cells for the
resulting immune responses could not be analysed in detail.
However, upon administration of a liposomal formulation that in
addition to the Tc epitope also included an influenza Th epitope,
improved effector activities were observed. Both protective and
therapeutic vaccination with this diepitope Tc-ErbB2/Th-HA
liposomal construct induced stronger antitumour immunity than
vaccination with mono-epitope Tc-ErbB2 liposomes, accompanied
by the recruitment of a higher number of IFN-g-producing T cells
specific for the ErbB2 peptide TYLPTNASL. This strongly supports
a beneficial role of T-cell help in the induction of antitumour
immune responses. Therefore, the liposomal cancer vaccines
investigated in this study that combine Tc- and strong Th-epitopes
fused to an immunostimulatory lipopeptide anchor might provide
a means to increase immunogenicity and enhance the antitumour-
al activity of synthetic peptide vaccines. Such novel liposomal
vaccines might improve the efficiency of common peptide
vaccination strategies using individual peptides that have been
defined as potential tumour rejection antigens.
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